Showing 5131-5140 of 7316 results for "".
- LaserAway Aesthetic Dermatology Chain Welcomes Kelly Lohr as New Customer Officerhttps://practicaldermatology.com/news/laseraway-aesthetic-dermatology-chain-welcomes-kelly-lohr-new-customer-officer/2462909/LaserAway, a prominent aesthetic dermatology chain, has welcomed Kelly Lohr as its inaugural Chief Customer Officer, signaling a move into the health and beauty space, according to a press release from the company. With LaserAway's presence in 145 locations and experiencing significant de
- FDA Accepts sNDA for Dermavant's Tapinarof Cream, 1%https://practicaldermatology.com/news/tapinarof-1-cream-progresses-toward-approval-pediatric-eczema/2462895/The U.S. Food and Drug Administration (FDA) has accepted Dermavant's Supplemental New Drug Application (sNDA) for tapinarof cream, 1% (VTAMA®), for the treatment of atopic dermatitis in (AD), according to a news release from the manufacturer. The FDA assigned a Prescription Drug User Fee
- La Roche-Posay Unveils New Serum to Combat Dark Spotshttps://practicaldermatology.com/news/la-roche-posay-unveils-new-serum-combat-dark-spots/2462880/La Roche-Posay has announced the launch of its Mela B3 Dark Spot Serum & Mela B3 UV Daily Moisturizer SPF 30 products. Powered by Melasyl™, the manufacturer said in a news release, L'Oreal's multi-patented ingredient derived from 18 years of research, represents "a breakthrough in pig
- Allergan Calls for Real Patient Stories in New Campaignhttps://practicaldermatology.com/news/allergan-calls-real-patient-stories-new-campaign/2462879/Allergan Aesthetics has announced that it is inviting consumers to participate in upcoming campaigns for their flagship brands, including BOTOX® Cosmetic, the JUVÉDERM® collection of fillers. Both current and prospective patients can now apply for a chance to feature in future brand promo
- LEVEL UP: Upadacitinib Shows Superior Efficacy in ADhttps://practicaldermatology.com/news/level-study-upadacitinib-shows-superior-efficacy-ad/2462870/New topline results evaluating the efficacy and safety of upadacitinib for adults and adolescents with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable suggested that treatment with the drug was effective.<
- Abrocitinib Cost-Effective Compared to Standard of Care for Atopic Dermatitis Treatment: Studyhttps://practicaldermatology.com/news/abrocitinib-cost-effective-compared-standard-care-atopic-dermatitis-treatment-japan/2462838/New research from a study of Japanese patients suggests that abrocitinib showed superior efficacy and safety compared to the standard of care (SoC). Recent findings from the JAK-1 Atopic Dermatitis Efficacy and Safety (JADE) program's Phase 3 trials have unveiled promising insights into th
- Impact of Alopecia Areata on Pediatric Patients and Their Families: Insights from a Single-Center Study in Turkeyhttps://practicaldermatology.com/news/impact-alopecia-areata-pediatric-patients-and-their-families-insights-single-center-study-turkey/2462829/Alopecia areata (AA) is known to impact the health-related quality of life (HRQoL) of affected individuals, yet there is a paucity of research focusing on its effects specifically in pediatric patients and their families. To address this gap, researchers recently conducted a single-center cross-s
- Oral and Topical Minoxidil for Male Androgenetic Alopecia Show Similar Efficacy: Analysishttps://practicaldermatology.com/news/oral-and-topical-minoxidil-male-androgenetic-alopecia-similar-efficacy-analysis/2462791/Low-dose oral minoxidil (5 mg once daily) was found to have similar effectiveness to topical minoxidil (5% twice per day) for the treatment of male androgenetic alopecia (AGA). The authors conducted the double-blind, placebo-controlled randomized clinical trial in Brazil aiming to evalua
- FDA Issues Alert for Counterfeit Botox Across Multiple U.S. Stateshttps://practicaldermatology.com/news/fda-issues-alert-counterfeit-botox-across-multiple-us-states/2462747/The U.S. Food and Drug Administration (FDA) has issued an alert regarding counterfeit botulinum toxin that has been detected in several states. The agency issued a statement on April 16 noting that it is aware of the issue and is working with the Centers for Disease Control (CDC), state
- Top Non-cosmetic Laser Indications Vary by Laser Typehttps://practicaldermatology.com/news/top-non-cosmetic-laser-indications-vary-laser-type/2462734/Treatment of psoriasis, vascular lesions, and hypertrophic disorders were the most common non-cosmetic indications for dermatologic use of excimer, vascular, and ablative lasers, respectively, based on data from more than 55,000 individuals. Non-cosmetic laser therapy in dermatology has e